HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chi, K.-H. Articles by Yen, S.-H. Search for Related Content PubMed PubMed Citation Articles by Chi, K.-H. Articles by Yen, S.-H.

Preclinical Evaluation of Locoregional Delivery of Radiolabeled Iododeoxyuridine and Thymidylate Synthase Inhibitor in a Hepatoma Model

Cancer Center and Department of Nuclear Medicine, Veterans General Hospital, National Yang-Ming University; and Institute of Radiation Science, National Yang-Ming University, Taipei, Taiwan, Republic of China

We report improved incorporation of the radiolabeled-thymidine analog [¹²⁵I/¹³¹I]5-iodo-2'-deoxyuridine ([¹²⁵I/¹³¹I]IdUrd) into DNA by the addition of Thymitaq, a thymidylate synthase inhibitor, as a strategy of molecular radiotherapy for hepatoma treatment. Methods: The synergistic effect of combination [¹²⁵I]IdUrd and Thymitaq in clonogenic survival and DNA incorporation was shown on the human hepatoma cell line Hep3B. Radiobiodistribution of intrahepatic arterially injected [¹²⁵]IdUrd and Thymitaq was studied in a rat N1S1 hepatoma model. In vivo therapeutic effects of locoregional delivery of both drugs were evaluated in mouse subcutaneous hepatoma and ascitic hepatoma models. Results: In a clonogenic assay, Thymitaq showed a synergistic effect with [¹²⁵I]IdUrd but not cold IdUrd. Thymitaq had a dose-dependent modulation effect on DNA-[¹²⁵I]IdUrd incorporation. The biodistribution study indicated a slower clearance rate of [¹²⁵I]IdUdR in the hepatoma as well as an initially higher uptake of [¹²⁵I]IdUrd into DNA when the [¹²⁵I]IdUrd was combined with Thymitaq. In vivo studies showed a superior therapeutic effect of combination Thymitaq and [¹²⁵I]IdUrd in both subcutaneous and ascites tumor models, but the combination of [¹³¹I]IdUrd and [¹²⁵I]IdUrd may be more effective than Auger electron emitters alone for the treatment of subcutaneous tumor. Conclusion: The strategy of locoregional delivery of [¹²⁵I/¹³¹I]IdUrd to a tumor site through an intrahepatic arterial, intratumoral, or intraperitoneal route in combination with Thymitaq is promising and may also have a favorable therapeutic index in vivo.

Key Words: hepatoma • radioactive iododeoxyuridine • AG337 • molecular radiotherapy • locoregional delivery

This article has been cited by other articles:

				N. Watanabe, H. Sawai, I. Ogihara-Umeda, S. Tanada, E. E. Kim, Y. Yonekura, and Y. Sasaki Molecular Therapy of Human Neuroblastoma Cells Using Auger Electrons of 111In-Labeled N-myc Antisense Oligonucleotides J. Nucl. Med., October 1, 2006; 47(10): 1670 - 1677. [Abstract] [Full Text] [PDF]

				K.-H. Chi, H.-E. Wang, Y.-S. Wang, S.-L. Chou, H.-M. Yu, Y.-H. Tseng, I.-M. Hwang, and W.-Y. Lui Antisense Thymidylate Synthase Electrogene Transfer to Increase Uptake of Radiolabeled Iododeoxyuridine in a Murine Model J. Nucl. Med., March 1, 2004; 45(3): 478 - 484. [Abstract] [Full Text]